Suspended ( To Assess Safety Cohort Per Protocol Design) . DURVALUMAB ( IMFINZY BY ASTRAZENECA ) And TOPOTECAN Or LURBINECTEDIN ( ZEPZELCA BY PHARMAMAR ) For The Treatment Of Relapsed Or Refractory Small Cell Lung Cancer .